Drug Search Results
More Filters [+]

Triflurane

Alternative Names: triflurane
Latest Update: None
Latest Update Note: None

Product Description

Triflurane was developed by Sanofi Aventis under the trade name Aubagio. And on September 12, 2012, the FDA approved the treatment of relapsing multiple sclerosis drugs. The drug is an immunomodulator that blocks the synthesis of pyrimidine by inhibiting dihydroorotate dehydrogenase. Triflurane is an in vivo active metabolite of leflunomide. (Sourced from: https://www.fluoropharm.com/news/1033.html)

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Triflurane

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title